Monday, December 23, 2024

News Articles and insight

Socially Responsible Investing: A...

Introduction:As awareness about social and environmental issues increases, more investors are embracing the...

Customizing Strike Prices for...

Introduction:In the world of options trading, strike prices are a crucial component of...

The Rise of Quantum...

Introduction:Quantum computing has emerged as a disruptive technology with significant potential to transform...

How Inflation Affects the...

Introduction:Inflation is a significant economic factor that impacts various industries, including the world...

Company information

Eli Lilly and Company
Sector: Healthcare
Industry: Drug Manufacturers - General
Symbol: LLY
Employees: 43000
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
AddressLilly Corporate Center, Indianapolis, IN, United States
CountryUnited States
Phone317 276 2000
Websitehttps://www.lilly.com

Live Information

Eli Lilly and Company
$778.18
Open $785.17
High $787.99
Marketcap 699.83B
Close $778.18
Low $773.07
Volume $1,202,289.00

History